With the increasing use of molecular genetics approaches for determination of potential disease-causing mutations, it is becoming more important to be able to interpret and act upon the provided results. As an example of such an instance, nearly 300 mutations have been identified in the myocilin (MYOC) gene, which is the most commonly mutated gene causing primary open angle glaucoma. Yet a lack of sufficient information exists for many of these variants, hindering their definitive classification. While the function of MYOC is unclear, biochemically, the vast majority of glaucoma-causing MYOC mutations result in protein non-secretion and intracellular insoluble aggregate formation in cultured cells. Previously we generated a Gaussia luciferase-based MYOC fusion protein to sensitively track secretion of the protein. Herein we applied this same assay to fourteen clinically-derived MYOC variants with varying degrees of predicted pathogenicity and compared the luciferase secretion results with the better established MYOC assay of western blotting. Eight of the variants (G12R, V53A, T204T, P254L, T325T, D380H, D395_E396insDP, and P481S) had not been biochemically assessed previously. Of these, P254L and D395_E396insDP demonstrated significant secretion defects from human embryonic kidney (HEK-293A) cells reminiscent of glaucoma-causing mutations. Overall, we found that the luciferase assay results agreed with western blotting for thirteen of the fourteen variants (93%), suggesting a strong concordance. These results suggest that the Gaussia luciferase assay may be used as a complementary or standalone assay for quickly assessing MYOC variant behavior, and anticipate that these results will be useful in MYOC variant curation and reclassification.